drugset / Trial / NCT04849650

PK Study of IV and Oral Amisulpride in Subjects With Severe Renal Impairment

NCT04849650

Phase 1 Completed 12 enrolled Acacia Pharma Ltd
Non-randomizedSingle-groupOpen-labelBasic science

Summary

The aim of the study is to understand how Amisulpride is taken up and distributed around the body and how quickly it is eliminated, when given by mouth and into a vein in adults with severe kidney disease. In addition it is important to understand how well tolerated Amisulpride is in this patient population. Healthy adults will be studied to provide a comparison.

Timeline

Start
2021-06-03
Primary completion
2021-10-30
Completion
2021-10-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Amisulpride Small molecule 10 mg Intravenous